International journal of pharmaceutics
Aug 24, 2025
PURPOSE: The development of a novel lipid-based formulation for apalutamide, a potent androgen receptor inhibitor for non-metastatic castration-resistant prostate cancer (nmCRPC), is explored in this study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Aug 2, 2025
Despite therapeutic advancements, metastatic and nonmetastatic castration-resistant prostate cancer (mCRPC and nmCRPC) remain incurable due to drug resistance, partly due to Androgen receptor (AR) gene abnormalities and splice variants. An Augmented ...
Journal of biomolecular structure & dynamics
Jul 26, 2023
Androgen receptor (AR), a steroid receptor, plays a pivotal role in the pathogenesis of prostate cancer (PCa). AR controls the transcription of genes that help cells avoid apoptosis and proliferate, thereby contributing to the development of PCa. Und...
International journal of molecular sciences
Aug 14, 2020
Gain-of-function mutations in human androgen receptor (AR) are among the major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols, as well...
Journal of chemical information and modeling
Feb 11, 2019
The nuclear androgen receptor (AR) is one of the most relevant biological targets of Endocrine Disrupting Chemicals (EDCs), which produce adverse effects by interfering with hormonal regulation and endocrine system functioning. This paper describes n...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.